Background: In 70-80% of cases, neuromyelitis optica (NMO) is associated with highly specific serum auto-antibodies to aquaporin-4 (termed AQP4-Ab or NMO-IgG). Recent evidence strongly suggests ...

have better long-term visual outcomes than those with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMSOD), but similar to those with multiple sclerosis.

Naismith et al. state that they preferentially recruited patients with severe optic neuritis (with ≤20/200 vision) and poor recovery (to <20/40 vision).This bias in selecting study participants ...

In this Healio Video Perspective from Hawaiian Eye 2025, Riad Sherif, MD, CEO of Oculis, discusses data on OCS-05 for the ...

OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ...

ON = optic neuritis; OND = other neurological diseases Table 2. Clinical findings, AQP4-Ab status in serum and CSF, and median AQP4-Ab serum titres in the various disease groups.